SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Omeros Corporation (NASDAQ: OMER) today announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company's Addiction...
SEATTLE, Nov. 19 /PRNewswire-FirstCall/ -- Omeros Corporation (NASDAQ: OMER) today announced unaudited financial results for the third quarter ended September 30, 2009. For the three months...
SEATTLE, WA, Nov. 13 /PRNewswire-FirstCall/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on...
SEATTLE, Wash., Oct. 7 /PRNewswire-FirstCall/ -- Omeros Corporation today announced the pricing of its initial public offering of 6.82 million shares of its common stock at a price of $10.00 per...
SEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- Omeros Corporation today announced the launch of its initial public offering of 6.82 million shares of its common stock. Omeros is a clinical-stage...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.19 | -4.4289044289 | 4.29 | 4.48 | 4.1 | 4845 | 4.23384231 | DE |
4 | -0.03 | -0.726392251816 | 4.13 | 4.5 | 3.95 | 4821 | 4.18421353 | DE |
12 | -0.28 | -6.39269406393 | 4.38 | 4.6 | 3.75 | 6880 | 4.18445959 | DE |
26 | 0.24 | 6.21761658031 | 3.86 | 4.6 | 3.61 | 7547 | 4.11848902 | DE |
52 | 1.1 | 36.6666666667 | 3 | 4.6 | 2.9 | 11766 | 3.66695393 | DE |
156 | 0.305 | 8.03689064559 | 3.795 | 4.6 | 2.15 | 10616 | 3.26250803 | DE |
260 | 0.688 | 20.164126612 | 3.412 | 4.6 | 2.15 | 14350 | 3.51372305 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales